4.7 Review

What makes a good drug target?

期刊

DRUG DISCOVERY TODAY
卷 17, 期 -, 页码 S24-S30

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.12.008

关键词

-

向作者/读者索取更多资源

Novel therapeutics in areas with a high unmet medical need are based on innovative drug targets. Although 'biologicals' have enlarged the space of druggable molecules, the number of appropriate drug targets is still limited. Discovering and assessing the potential therapeutic benefit of a drug target is based not only on experimental, mechanistic and pharmacological studies but also on a theoretical molecular druggability assessment, an early evaluation of potential side effects and considerations regarding opportunities for commercialization. This article defines key properties of a good drug target from the perspective of a pharmaceutical company.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, Carl F. Nising, Christoph Mahlert, Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Stefanie Hammer, Simone Greven, Joachim Schuhmacher, Manuela Braun, Ruprecht Zierz, Sabine Wittemer-Rump, Axel Harrenga, Frank Dittmer, Frank Reetz, Heiner Apeler, Rolf Jautelat, Hung Huynh, Karl Ziegelbauer, Bertolt Kreft

CANCER RESEARCH (2016)

Article Chemistry, Multidisciplinary

Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class

Hans-Georg Lerchen, Sven Wittrock, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Nils Griebenow, Anne-Sophie Rebstock, Sarah Johannes, Yolanda Cancho-Grande, Christoph Mahlert, Simone Greven, Carsten Terjung

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)

Article Oncology

Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis

Julia C. Meier, Bernard Haendler, Henrik Seidel, Philip Groth, Robert Adams, Karl Ziegelbauer, Bertolt Kreft, Georg Beckmann, Anette Sommer, Charlotte Kopitz

CANCER MEDICINE (2015)

Article Chemistry, Multidisciplinary

Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation

Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Sandra Berndt, Anette Sommer, Lisa Dietz, Anne-Sophie Rebstock, Sarah Johannes, Leo Marx, Hannah Joerissen, Christoph Mahlert, Simone Greven

CHEMISTRY-A EUROPEAN JOURNAL (2019)

Article Oncology

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344

Katrine Wickstroem, Urs B. Hagemann, Alexander Kristian, Christine Ellingsen, Anette Sommer, Heidrun Ellinger-Ziegelbauer, Uta Wirnitzer, Else-Marie Hagelin, Aasmund Larsen, Roger Smeets, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Antje M. Wengner, Lars Linden, Dominik Mumberg, Alan S. Cuthbertson

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Article Oncology

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin

TARGETED ONCOLOGY (2019)

Meeting Abstract Hematology

In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, Allison Kaeding, Christoph Schatz, Anette Sommer, Soheil Meshinchi, E. Anders Kolb, Sonali Barwe

Article Biochemical Research Methods

Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads

Hans-Georg Lerchen, Beatrix Stelte-Ludwig, Anette Sommer, Sandra Berndt, Anne-Sophie Rebstock, Sarah Johannes, Christoph Mahlert, Simone Greven, Lisa Dietz, Hannah Joerissen

BIOCONJUGATE CHEMISTRY (2020)

Article Oncology

IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies

Dennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, Antje Margret Wengner, Oliver von Ahsen, Pascale Buchmann, Stephan Marsch, Christoph Mahlert, Simone Greven, Lisa Dietz, Michael Erkelenz, Ruprecht Zierz, Sandra Johanssen, Dominik Mumberg, Anette Sommer

CANCERS (2020)

Article Oncology

Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine

Vincent Chen, Shigeki Umemura, Yumin Han, Renuka Raman, Robin Tucker, Joeffrey Chahine, In-Kyu Kim, Christoph Schatz, Sabine Zitzmann-Kolbe, Anette Sommer, Masanori Onda, Trevor Lee, Yongfeng He, Giuseppe Giaccone

Summary: This study demonstrates that anetumab ravtansine inhibits the growth of MSLN positive thymic carcinoma cells both in vitro and in vivo. The results show that ARav has potential as a novel therapy for thymic carcinoma, especially in cases where traditional therapies have limited effectiveness.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties

Anette Sommer, Sandra Berndt, Hans-Georg Lerchen, Sabrina Forveille, Allan Sauvat, Dominik Mumberg, Guido Kroemer, Oliver Kepp

Summary: The study characterizes the mode of action of antibody-drug conjugates (ADCs) and finds that they can activate immune responses and induce immunogenic cell death, contributing to their antineoplastic effects.

ONCOIMMUNOLOGY (2022)

Article Biochemical Research Methods

A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy

Niels Boehnke, Markus Berger, Nils Griebenow, Antje Rottmann, Michael Erkelenz, Stefanie Hammer, Sandra Berndt, Judith Guenther, Antje M. Wengner, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Lisa Dietz, Hannah Jorissen, Naomi Barak, Ulf Boemer, Roman C. Hillig, Uwe Eberspaecher, Jorg Weiske, Anja Giese, Dominik Mumberg, Carl Friedrich Nising, Hilmar Weinmann, Anette Sommer

Summary: A new class of NAMPT inhibitors as ADC payloads was developed, optimizing their structures to create highly potent effector chemistries. The optimized NAMPTi-ADCs demonstrated potent in vivo antitumor efficacy with a very good selectivity profile.

BIOCONJUGATE CHEMISTRY (2022)

Article Cell Biology

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer

Richard E. Beatson, Ana C. Parente-Pereira, Leena Halim, Domenico Cozzetto, Caroline Hull, Lynsey M. Whilding, Olivier Martinez, Chelsea A. Taylor, Jana Obajdin, Kim Ngan Luu Hoang, Benjamin Draper, Ayesha Iqbal, Tom Hardiman, Tomasz Zabinski, Francis Man, Rafael T. M. de Rosales, Jinger Xie, Fred Aswad, Daniela Achkova, Chung-Yang Ricardo Joseph, Sara Ciprut, Antonella Adami, Helge G. Roider, Holger Hess-Stumpp, Balazs Gyorffy, Jelmar Quist, Anita Grigoriadis, Anette Sommer, Andrew N. J. Tutt, David M. Davies, John Maher

Summary: Expanding circulating Vγ9Vδ2 T cells in specific culture medium can enhance the therapeutic efficacy and activity of γδT cells in cancer immunotherapy, particularly showing potential treatment activity in leukemia and solid tumor models.

CELL REPORTS MEDICINE (2021)

Meeting Abstract Oncology

Development of potent and selective antibody-drug conjugates with pyrrole-based KSP inhibitors as novel payload class

Hans-Georg Lerchen, Sven Wittrock, Nils Griebenow, Mario Lobell, Anne-Sophie Rebstock, Yolanda Cancho-Grande, Beatrix Stelte-Ludwig, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt, Carsten Terjung, Heiner Apeler, Bertolt Kreft, Rolf Jautelat

CANCER RESEARCH (2017)

Article Neurosciences

Alzheimer Amyloid Peptide Aβ42 Regulates Gene Expression of Transcription and Growth Factors

Christian Barucker, Anette Sommer, Georg Beckmann, Murat Eravci, Anja Harmeier, Carola G. Schipke, Damian Brockschnieder, Thomas Dyrks, Veit Althoff, Paul E. Fraser, Lili-Naz Hazrati, Peter St George-Hyslop, John C. S. Breitner, Oliver Peters, Gerhard Multhaup

JOURNAL OF ALZHEIMERS DISEASE (2015)

Review Pharmacology & Pharmacy

Illuminating the druggable genome: Pathways to progress

Karlie R. Sharma, Christine M. Colvis, Griffih P. Rodgers, Douglas M. Sheeley

Summary: There are many genes within the druggable genome that have not been studied, and the US National Institutes of Health's program provides resources to explore these genes, with the potential for rapid impact on human health.

DRUG DISCOVERY TODAY (2024)

Review Pharmacology & Pharmacy

Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment

Mohammad Sameer Khan, B. H. Jaswanth Gowda, Waleed H. Almalki, Tanuja Singh, Amirhossein Sahebkar, Prashant Kesharwani

Summary: Mitochondria-specific functional liposomes hold great potential for cancer therapy. This review discusses the association between mitochondria and tumor formation, as well as the advantages of liposomes in delivering drugs to mitochondria.

DRUG DISCOVERY TODAY (2024)

Review Pharmacology & Pharmacy

Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities

Choong Yong Ung, Cristina Correia, Hu Li, Christopher M. Adams, Jennifer J. Westendorf, Shizhen Zhu

Summary: With increasing human life expectancy, the global medical burden of chronic diseases is growing. Chronic diseases often involve malfunctioning of multiple organs, and understanding the interorgan crosstalk is crucial to understanding the etiology of chronic diseases. Researchers have proposed the locked-state model (LoSM) and cutting-edge systems biology and artificial intelligence strategies to decipher chronic multiorgan locked states. The findings have important clinical implications for improving treatments for chronic diseases.

DRUG DISCOVERY TODAY (2024)